tetano
Editor, Senior Moderator
Sci Rep. 2018 Mar 29;8(1):5364. doi: 10.1038/s41598-018-23712-9.
[h=1]Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.[/h] Meseda CA[SUP]1[/SUP], Atukorale V[SUP]1[/SUP], Soto J[SUP]1[/SUP], Eichelberger MC[SUP]2[/SUP], Gao J[SUP]2[/SUP], Wang W[SUP]3[/SUP], Weiss CD[SUP]3[/SUP], Weir JP[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza subtypes such as H7 have pandemic potential since they are able to infect humans with severe consequences, as evidenced by the ongoing H7N9 infections in China that began in 2013. The diversity of H7 viruses calls for a broadly cross-protective vaccine for protection. We describe the construction of recombinant modified vaccinia virus Ankara (MVA) vectors expressing the hemagglutinin (HA) or neuraminidase (NA) from three H7 viruses representing both Eurasian and North American H7 lineages - A/mallard/Netherlands/12/2000 (H7N3), A/Canada/rv444/2004 (H7N3), and A/Shanghai/02/2013 (H7N9). These vectors were evaluated for immunogenicity and protective efficacy against H7N3 virus in a murine model of intranasal challenge. High levels of H7-, N3-, and N9-specific antibodies, including neutralizing antibodies, were induced by the MVA-HA and MVA-NA vectors. Mice vaccinated with MVA vectors expressing any of the H7 antigens were protected, suggesting cross-protection among H7 viruses. In addition, MVA vectors expressing N3 but not N9 elicited protection against H7N3 virus challenge. Similar outcomes were obtained when immune sera from MVA vector-immunized mice were passively transferred to na?ve mice prior to challenge with the H7N3 virus. The results support the further development of an MVA vector platform as a candidate vaccine for influenza strains with pandemic potential.
PMID: 29599502 PMCID: PMC5876369 DOI: 10.1038/s41598-018-23712-9
Free PMC Article
[h=1]Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.[/h] Meseda CA[SUP]1[/SUP], Atukorale V[SUP]1[/SUP], Soto J[SUP]1[/SUP], Eichelberger MC[SUP]2[/SUP], Gao J[SUP]2[/SUP], Wang W[SUP]3[/SUP], Weiss CD[SUP]3[/SUP], Weir JP[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza subtypes such as H7 have pandemic potential since they are able to infect humans with severe consequences, as evidenced by the ongoing H7N9 infections in China that began in 2013. The diversity of H7 viruses calls for a broadly cross-protective vaccine for protection. We describe the construction of recombinant modified vaccinia virus Ankara (MVA) vectors expressing the hemagglutinin (HA) or neuraminidase (NA) from three H7 viruses representing both Eurasian and North American H7 lineages - A/mallard/Netherlands/12/2000 (H7N3), A/Canada/rv444/2004 (H7N3), and A/Shanghai/02/2013 (H7N9). These vectors were evaluated for immunogenicity and protective efficacy against H7N3 virus in a murine model of intranasal challenge. High levels of H7-, N3-, and N9-specific antibodies, including neutralizing antibodies, were induced by the MVA-HA and MVA-NA vectors. Mice vaccinated with MVA vectors expressing any of the H7 antigens were protected, suggesting cross-protection among H7 viruses. In addition, MVA vectors expressing N3 but not N9 elicited protection against H7N3 virus challenge. Similar outcomes were obtained when immune sera from MVA vector-immunized mice were passively transferred to na?ve mice prior to challenge with the H7N3 virus. The results support the further development of an MVA vector platform as a candidate vaccine for influenza strains with pandemic potential.
PMID: 29599502 PMCID: PMC5876369 DOI: 10.1038/s41598-018-23712-9
Free PMC Article